

**From:** "Dimmick, Lisa" <lisa.dimmick@us.nucletron.com>  
**To:** "Barbara Park" <bpark@mde.state.md.us>  
**Date:** 6/11/2007 11:12:48 AM  
**Subject:** RE: SS&D

Only delete "Alpha, Beta, Gamma format"

-----Original Message-----

From: Barbara Park [mailto:bpark@mde.state.md.us]  
Sent: Monday, June 11, 2007 10:13 AM  
To: Dimmick, Lisa  
Subject: RE: SS&D

Why does he want all that deleted? I will check back at my rationale.

b

>>> "Dimmick, Lisa" <lisa.dimmick@us.nucletron.com> 06/11/07 9:51 AM  
>>>

Hi Babara,

Interluminal and intraluminal were used in the sheet. I did the same rationalization-- inter versus intra for the "lumen." But, I think you are right with interluminal. Thanks for verifying.

The correction Leo sent was on page 5 under Prototype Testing and it is just a deletion for clarification purposes.

"...The device was developed under ISO 9001:2000 and EN ISO 13485:2003 (KEMA certificate #55859) Quality Systems Requirements. The manufacturer indicates that the prototype was tested to conform to design specifications and that functional and safety aspects of the system (Alpha, Beta, Gamma format) were checked under normal and single fault conditions. New software for the device was tested and passed under the manufacturer's Treatment Console Software Test-Plan..."

Lisa

-----Original Message-----

From: Barbara Park [mailto:bpark@mde.state.md.us]  
Sent: Monday, June 11, 2007 9:40 AM

**From:** "Dimmick, Lisa" <lisa.dimmick@us.nucletron.com>  
**To:** "Barbara Park" <bpark@mde.state.md.us>  
**Date:** 6/11/2007 9:52:26 AM  
**Subject:** RE: SS&D

Hi Babara,

Interluminal and intraluminal were used in the sheet. I did the same rationalization-- inter versus intra for the "lumen." But, I think you are right with interluminal. Thanks for verifying.

The correction Leo sent was on page 5 under Prototype Testing and it is just a deletion for clarification purposes.

"...The device was developed under ISO 9001:2000 and EN ISO 13485:2003 (KEMA certificate #55859) Quality Systems Requirements. The manufacturer indicates that the prototype was tested to conform to design specifications and that functional and safety aspects of the system (Alpha, Beta, Gamma format) were checked under normal and single fault conditions. New software for the device was tested and passed under the manufacturer's Treatment Console Software Test-Plan..."

Lisa

-----Original Message-----

**From:** Barbara Park [mailto:bpark@mde.state.md.us]  
**Sent:** Monday, June 11, 2007 9:40 AM  
**To:** Dimmick, Lisa  
**Subject:** Re: SS&D

Yes I got it, unzipped it and am working on it.

I have contention with the words interluminal vs intraluminal. This is on page 4 under d. Inter would mean within the lumen and intra would mean between lumens ( luminae). I would think it would be inter and I think it is that way on other sheets but I have just gotten there to

that point and have not checked.

Yes, just send page number, etc. Also, I am primary reviewer and Ray is concurrence, just fyi--I am reversing that at the end page.

b

>>> "Dimmick, Lisa" <lisa.dimmick@us.nucletron.com> 06/11/07 9:25 AM

>>>

Hi Barbara,

I was just checking if you received the draft SS&D last Friday. I

tried

a couple times but the word file was too large and exceeded you e-mail

sized limit -at least that is what the failure notice indicated. My

husband did zip it and re-sent it late Friday afternoon. Let me know

if

you received it and it opened OK. I have one other minor correction

that Leo sent to me that I will forward shortly. If you received the

file last week, then I 'll just let you know the page and line # for

the

new correction.

Thanks,

Lisa

Lisa Dimmick

Director of QA& RA, RSO

Nucletron Corporation

Office: +1 443 545 2196

Mobile: +1 (443) 253 9172

[lisa.dimmick@us.nucletron.com](mailto:lisa.dimmick@us.nucletron.com)

Visit our website: [www.nucletron.com](http://www.nucletron.com)

Nucletron supports the 12th International Conference "Optimal Use of Advanced Radiotherapy in Multimodality Oncology" in Rome. Please visit the website [www.rome2007.org](http://www.rome2007.org) for further information.

---

This e-mail and any attachment sent with it are intended exclusively for the addressee(s), and may not be passed on to, or made available for use by any person other than the addressee(s). Nucletron Corporation rules out any and every liability resulting from any electronic transmission.

---

---

The information contained in this communication may be confidential, is intended only for the use of the recipient named above, and may be legally privileged.

If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited.

To: Dimmick, Lisa  
Subject: Re: SS&D

Yes I got it, unzipped it and am working on it.

I have contention with the words interluminal vs intraluminal. This is  
on page 4 under d. Inter would mean within the lumen and intra would mean between lumens ( luminae). I would think it would be inter and I think it is that way on other sheets but I have just gotten there to that point and have not checked.

Yes, just send page number, etc. Also, I am primary reviewer and Ray is concurrence, just fyi—I am reversing that at the end page.

b

>>> "Dimmick, Lisa" <lisa.dimmick@us.nucletron.com> 06/11/07 9:25 AM

>>>

Hi Barbara,

I was just checking if you received the draft SS&D last Friday. I

tried

a couple times but the word file was too large and exceeded you e-mail sized limit -at least that is what the failure notice indicated. My husband did zip it and re-sent it late Friday afternoon. Let me know

if



you received it and it opened OK. I have one other minor correction that Leo sent to me that I will forward shortly. If you received the file last week, then I'll just let you know the page and line # for the new correction.

Thanks,

Lisa

Lisa Dimmick

Director of QA& RA, RSO

Nucletron Corporation

Office: +1 443 545 2196

Mobile: +1 (443) 253 9172

[lisa.dimmick@us.nucletron.com](mailto:lisa.dimmick@us.nucletron.com)

Visit our website: [www.nucletron.com](http://www.nucletron.com)

Nucletron supports the 12th International Conference "Optimal Use of Advanced Radiotherapy in Multimodality Oncology" in Rome. Please visit the website [www.rome2007.org](http://www.rome2007.org) for further information.

---

This e-mail and any attachment sent with it are intended exclusively for the addressee(s), and may not be passed on to, or made available for

use by any person other than the addressee(s). Nucletron Corporation rules out any and every liability resulting from any electronic transmission.

---

---

The information contained in this communication may be confidential, is intended only for the use of the recipient named above, and may be legally privileged.

If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited.

If you have received this communication in error, please re-send this communication to the sender and delete the original message and any copy of it from your computer system. Thank you.

---

<<<<GWIASIG 0.07>>>>

If you have received this communication in error, please re-send this communication to the sender and delete the original message and any copy of it from your computer system. Thank you.

---

<<<<GWIASIG 0.07>>>>